A Phase 2 clinical trial investigating the ability of CX717 to improve breathing in patients with spinal cord injury

Trial Profile

A Phase 2 clinical trial investigating the ability of CX717 to improve breathing in patients with spinal cord injury

Planning
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs CX 717 (Primary)
  • Indications Respiratory insufficiency
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jun 2017 New trial record
    • 14 Jun 2017 According to a RespireRx Pharmaceuticals media release, the company is planning to file an INDand initiate this trial during 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top